Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 137,400 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $1.28 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.
Vesting of the stock options is subject to the employees' continued service to Zentalis on each vesting date.
About Zentalis PharmaceuticalsZentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Contact:Aron Feingold, VP, IR & Corp Commsir@zentalis.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
7 minutes ago
- Associated Press
Aggreko's North American Headquarters Replaces Diesel with Biofuel, Reducing CO2 by up to 60%
HOUSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Aggreko, a global leader in energy solutions, announced that the company has transitioned four of its North American locations to hydrotreated vegetable oil (HVO), negating the need for diesel in any internal needs. The locations include the company's North American headquarters in Pearland, TX, as well as the facilities in New Iberia, San Francisco, and Los Angeles. Thanks to the transition, the company has reduced diesel-related carbon emissions at these two sites by up to an estimated 60%. In replacing diesel with the HVO, Aggreko is instead using biofuel for its onsite operations in the four locations, including the maintenance and testing of generators and fuel for forklifts and service vehicles. At Aggreko service centers, technicians use fuel to ensure generators and other power solutions are ready for customer delivery, as well as for general onsite transportation needs. As Aggreko's generators can run on biofuel in addition to diesel, even if a customer is planning to operate a generator using diesel, Aggreko can rely on HVO to test the unit. 'One of the great benefits of our diesel power solutions is how all of them can run on biofuels like HVO, and our service centers provide a great opportunity to demonstrate this for our customers,' says Todd Aston, Regional Vice President of Sustainability at Aggreko. 'In replacing our internal fuel needs with a biofuel option, we realized a dramatic CO2 emissions reduction of up to 60%. We are proud to take a leading role among energy solution providers in embracing alternative fuels, and we look forward to transitioning to HVO at more of our service centers.' Following the successful transition to HVO at Pearland, New Iberia, San Francisco, and Los Angeles, Aggreko is finalizing the replacement of diesel with HVO for internal use at additional facilities across the United States. Aggreko's transition to HVO forms a key part of the company's Energizing Change sustainability campaign, which includes installing rooftop solar at service centers to support reaching 100% renewable electricity at service centers. To learn more about Energizing Change, visit About Aggreko Aggreko is a global leader in energy solutions, providing rapidly deployable, modular power and temperature control solutions for however long they're needed. We're highly skilled sector specialists, bringing together our proprietary application know-how and engineering capability to deliver efficient, reliable and sustainable energy solutions. With experience of working in the most demanding environments, we're available for customers when they need us most, from emergency critical services to longer-term energy solutions. We're continually investing in more sustainable products, fuels and services to make greener solutions accessible to customers, helping them wherever they are on their energy transition journey. Founded in 1962, we are headquartered in the UK and employ over 6,800 people worldwide. For more information, please visit our website at Home | Aggreko. Media Contact Justin Williams Trevi Communications for Aggreko [email protected] +1 (978) 539-7157 A photo accompanying this announcement is available at
Business Wire
21 minutes ago
- Business Wire
Welldoc Works with Lilly to Launch a New Personalized Health & Medicine Platform for Those Prescribed Lilly's Incretin Therapies
COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Health™ Personalized Health & Medicine Platform* (Lilly Health app) with its cardiometabolic digital health platform. The Lilly Health app is designed to support a tailored patient experience for individuals interested in or using Eli Lilly and Company's incretin-based therapies, for the treatment of cardiometabolic conditions, such as obesity, type 2 diabetes and moderate- to-severe obstructive sleep apnea and obesity. Initially, the Lilly Health app will be available for patients prescribed Zepbound® (tirzepatide)** or Mounjaro® (tirzepatide)**. Lilly and Welldoc aim to build a more seamless patient experience through educational resources and targeted support. The Lilly Health app will provide features to help patients with their cardiometabolic health goals and weight, such as medication logging, reminders, device connectivity and health data tracking. "We are incredibly proud to expand our impactful work with Lilly. Welldoc's robust and AI-powered digital health platform is uniquely equipped to be a powerful foundation for the Lilly Health app,' said Kevin McRaith, President and CEO of Welldoc. 'Our proven ability to integrate complex data, deliver personalized insights and support individuals across multiple cardiometabolic conditions positions us as the ideal technology partner for Lilly's ambitious vision. We are confident that our scalable and secure platform will enable Lilly Health to deliver a truly transformative and connected experience for patients.' The Lilly Health app is built upon Welldoc's well-established digital cardiometabolic platform, which provides individuals with extensive device and data connectivity, in-app nutrition and exercise resources, and comprehensive trends and insights to help individuals manage complex cardiometabolic conditions with their providers and optimize their overall health over time. About Welldoc Welldoc ®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc's comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs. Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 50+ patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, The Wall Street Journal and The Economist. The company has been named the 'Best Overall Digital Health Company' by MedTech Breakthrough for the past two years and was selected as a winner of the 2025 AI Excellence Awards by Business Intelligence Group, 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit Follow us on LinkedIn and X. *Lilly Health™ Personalized Health & Medicine Platform Lilly Health Personalized Health & Medicine Platform is intended for use as a health management aid for adult patients 18 years or older who have been prescribed Zepbound® (tirzepatide) or Mounjaro® (tirzepatide). Lilly Health provides Zepbound and Mounjaro users with medication reminders, medication dose logging, and health data logging. Lilly Health is not intended to provide treatment decisions or replace the care and advice of a licensed Health Care Provider (HCP). All medical analysis and treatment plans should be performed by a licensed HCP. ** Zepbound® (tirzepatide) Zepbound is an injectable prescription medicine that may help adults with: obesity, or some adults with overweight who has have weight-related medical problems to lose excess body weight and keep the weight off moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. See for full indications of use. **Mounjaro® (tirzepatide) Mounjaro is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age. See for full indications of use.
USA Today
22 minutes ago
- USA Today
Kate Spade died 7 years ago: What to know about the iconic fashion designer
Kate Spade died 7 years ago: What to know about the iconic fashion designer Show Caption Hide Caption Kate Spade's legacy Learn more on the death of handbag designer Kate Spade. CBC - Business Kate Spade, the designer who helped characterize 1990s fashion with her iconic handbags, died by suicide seven years ago this week. Spade's death on June 5, 2018, stunned the fashion world, highlighting the silent struggles behind one of the industry's biggest names and, along with the death of Anthony Bourdain three days later, sparked a broader conversation about mental health amidst fame and success. A two-time Council of Fashion Designers of America award winner, Spade left behind a brand that captivated young women in the '90s and early aughts that endures today. Who was Kate Spade? Born Katherine Brosnahan in Kansas City, she co-founded her eponymous designer brand in 1993 with her future husband and business partner Andy Spade, the brother of comedian David Spade, in their New York City apartment. Started with hand-taped prototypes, Kate Spade became a rapid success, expanding to shoes, luggage and other accessories. Spade relinquished any ownership of her brand in the mid-2000s, which would change hands a few times before landing at Tapestry, Inc., formerly Coach, Inc., after a $2.4 billion purchase in 2017. How did Kate Spade die? Spade was found dead in her Upper East Side apartment in New York City. She was 55. Her cause of death was ruled suicide by hanging. In a statement reported by media at the time, Andy Spade said his late wife had "suffered from depression and anxiety for many years" but "was actively seeking help and working closely with her doctors to treat her disease, one that takes far too many lives." Her death was followed by Anthony Bourdain's suicide three days later. "There was no indication and no warning that she would do this. It was a complete shock," Andy Spade continued. "There were personal demons she was battling." Kate Spade's best friend Elyce Arons, who is writing a memoir titled "We Might Just Make It After All" about their friendship, said the couple "were trying to work things out," she told People in an interview published June 3. The book is set for release on June 17 through Simon & Schuster. Kate Spade's daughter Frances was namesake of her new brand Spade's daughter Frances Beatrice Valentine Spade was 13 at the time of her death. Police reported at the time that she left Frances, now 20, a note. In 2016, Kate Spade turned to a new brand based around her daughter, the luxury footwear and handbag company Frances Valentine, with which she remained active until her death. If you or someone you know may be struggling with suicidal thoughts, you can call 988 any time day or night, or chat online. Crisis Text Line also provides free, 24/7, confidential support via text message to people in crisis when they dial 741741.
